Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Depreciation and Depletion (2016 - 2018)

Cytokinetics (CYTK) has disclosed Depreciation and Depletion for 3 consecutive years, with -$359000.0 as the latest value for Q4 2018.

  • On a quarterly basis, Depreciation and Depletion fell 160.85% to -$359000.0 in Q4 2018 year-over-year; TTM through Dec 2018 was $1.2 million, a 36.84% decrease, with the full-year FY2025 number at $10.1 million, up 6.32% from a year prior.
  • Depreciation and Depletion was -$359000.0 for Q4 2018 at Cytokinetics, down from $268000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $673000.0 in Q1 2018 to a low of -$359000.0 in Q4 2018.
  • A 3-year average of $364777.8 and a median of $439000.0 in 2017 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: skyrocketed 222.4% in 2017, then tumbled 160.85% in 2018.
  • Cytokinetics' Depreciation and Depletion stood at $183000.0 in 2016, then surged by 222.4% to $590000.0 in 2017, then crashed by 160.85% to -$359000.0 in 2018.
  • Per Business Quant, the three most recent readings for CYTK's Depreciation and Depletion are -$359000.0 (Q4 2018), $268000.0 (Q3 2018), and $618000.0 (Q2 2018).